| Terumo Corporation and Diabeloop SA. Enter into Comprehensive Strategic Partnership Agreement to Expand Their Diabetes Care Offering | https://www.terumo-europe.com/en-emea/news/terumo-corporation-and-diabeloop-sa-enter-into-comprehensive-strategic-partnership-agreement-to-expand-their-diabetes-care | Terumo Corporation and Diabeloop SA. Enter into Comprehensive Strategic Partnership Agreement to Expand Their Diabetes Care Offering | TOKYO, JAPAN and PARIS, FRANCE | 11/16/2021 11:00:00 PM | <h4 style="text-align:justify;">Terumo Corporation, a global leader in medical technology and the French company Diabeloop, a pioneer in therapeutic AI, announced today that they have signed an agreement for a comprehensive strategic partnership. With this agreement, in addition to the current joint development of the AID system for Japan, they will work closely to bring Automated Insulin Delivery solutions to Europe with potential further global expansion.<br><br></h4> |
| Terumo to Develop Smartphone-type Device to Control Insulin Pump | https://www.terumo-europe.com/en-emea/news/terumo-to-develop-smartphone-type-device-to-control-insulin-pump | Terumo to Develop Smartphone-type Device to Control Insulin Pump | TOKYO, JAPAN | 11/7/2021 11:00:00 PM | <h4 style="text-align:justify;">Terumo Corporation (TSE: 4543) today announced that it has partnered with an European company to co-develop a new technology to enable MEDISAFE WITH insulin patch pump to be controlled by a smartphone-type device. With this upgrade, Terumo aims to enhance the operability of MEDISAFE WITH as well as allowing insulin pump therapy to be harmonized into the day-to-day life of people with diabetes. The smartphone-type device will be dedicated to controlling the MEDISAFE WITH.</h4><h4><br></h4> |
| Terumo Celebrates 100th Anniversary of Contributing to Society Through Healthcare | https://www.terumo-europe.com/en-emea/news/terumo-celebrates-100th-anniversary-of-contributing-to-society-through-healthcare | Terumo Celebrates 100th Anniversary of Contributing to Society Through Healthcare | TOKYO, JAPAN | 9/16/2021 10:00:00 PM | <p>Terumo Corporation (TSE: 4543), a global leader in medical technology, today celebrates its 100th anniversary. The company, based in Tokyo, boasts over 25,000 associates worldwide, providing products and services to more than 160 countries and regions across the globe. <br></p> |
| MASTER DAPT, a landmark trial on abbreviated DAPT post-implantation of Ultimaster™ DES in HBR patients | https://www.terumo-europe.com/en-emea/news/master-dapt-a-landmark-trial-on-abbreviated-dapt-post-implantation-of-ultimaster™-des-in-hbr-patients | MASTER DAPT, a landmark trial on abbreviated DAPT post-implantation of Ultimaster™ DES in HBR patients | LEUVEN, BELGIUM | 8/29/2021 10:00:00 PM | <p><span style="letter-spacing:-0.1px;">Final results released @ ESC 2021 and simultaneously published in New England Journal of Medicine and Circulation</span><br></p> |
| Terumo and UMCU strengthen their partnership to develop solutions in Interventional Oncology | https://www.terumo-europe.com/en-emea/news/terumo-and-umcu-strengthen-their-partnership-to-develop-solutions-in-interventional-oncology | Terumo and UMCU strengthen their partnership to develop solutions in Interventional Oncology | Deventer, Tokyo, Utrecht | 7/18/2021 10:00:00 PM | <p>Terumo Europe and University Medical Center Utrecht signed a Memorandum of Understanding<br></p> |
